Table 3. Summary of irradiated sporozoite immune reactivities against a subset of the panel of 27 P. falciparum proteins and four known antigens.

Source	Antigen	No. volunteers responding	Percent volunteers responding	SI*	SFC†
Test Plasmodium proteins	2	8	100	3.3 ± 1.3	122.7 ± 90.6
	5	7	87.5	2.8 ± 1.1	101.8 ± 74.0
	18	6	75	2.2 ± 0.2	58.4 ± 24.4
	3	6	75	2.6 ± 0.4	119.1 ± 69.5
	22	5	62.5	2.9 ± 0.9	108.4 ± 78.1
	20	4	50	2.5 ± 0.5	74.8 ± 40.1
	11	4	50	3.1 ± 0.8	81.3 ± 47.9
	21	4	50	2.3 ± 0.3	48.2 ± 16.5
	13	4	50	2.9 ± 1.1	92.2 ± 50.1
	1	3	37.5	2.4 ± 0.2	61.4 ± 42.0
	17	3	37.5	2.4 ± 0.3	57.6 ± 34.5
	12	3	37.5	2.2 ± 0.3	48.2 ± 16.5
	16	2	25	2.2 ± 0.3	27.2 ± 23.3
	15	2	25	2.5 ± 0.7	28.8 ± 20.0
	19	2	25	2.7 ± 0.6	31.3 ± 22.6
	9	2	25	2.5 ± 0.2	32.0 ± 28.3
	Range	2-8	25-100	2.0-5.9	10.0-254.0
	Mean	4.1	50.8	2.6	80.3
Known Plasmodium antigens	CSP	3	37.5	2.7 ± 0.6	41.6 ± 20.1
	SSP2	5	62.5	2.9 ± 1.0	97.2 ± 82.0
	LSA1	2	25	3.2 ± 1.4	34.2 ± 29.0
	EXP1	1	12.5	3.4	41.3
	Range	1-5	12.5-62.5	2.0-4.2	12.3-230.0
	Mean	2.75	34.4	2.9	65.5
Control epitopes‡	CMV, EBV, influenza	7	87.5§	4.0 ± 2.2	59.0 ± 30.5

CMV, cytomegalovirus; EBV, Epstein-Barr virus.

^*SI (stimulation index) indicates fold over background response to media and negative control peptide (HLA-A2 restricted HIV gag protein, residues 77-85), mean ± SD.

^†Net SFC indicates counts above background counts to media and negative control peptide (HLA-A2 restricted HIV gag, residues 77-85), mean ± SD.

^‡Positive control peptides derived from CMV phosphoprotein, residues 495-503 (HLA-A2); influenza virus matrix protein, residues 58-66 (HLA-A2); influenza virus nucleoprotein, residues 265-273 (HLA-A3); and EBV EBNA3, residues 339-347 (HLA-B8).

^§Positive responses to control epitopes were detected in all four mock-immunized volunteers.